OPTIMAX HOLDINGS BERHAD
KLSE (MYR): OPTIMAX (0222)
You're accessing 15 mins delay data. Turn on live stream now to enjoy real-time data!
Last Price
0.69
Today's Change
+0.005 (0.73%)
Day's Change
0.675 - 0.69
Trading Volume
120,800
Overview
Market Cap
373 Million
NOSH
540 Million
Avg Volume (4 weeks)
312,484
4 Weeks Range
0.675 - 0.70
4 Weeks Price Volatility (%)
60.00%
52 Weeks Range
0.65 - 0.845
52 Weeks Price Volatility (%)
20.51%
Previous Close
0.685
Open
0.68
Bid
0.675 x 49,400
Ask
0.69 x 68,300
Day's Range
0.675 - 0.69
Trading Volume
120,800
Financial Highlight
Latest Quarter | Ann. Date
30-Jun-2023 [#2] | 24-Aug-2023
Next QR | Est. Ann. Date
30-Sep-2023 | 29-Nov-2023
T4Q P/E | EY
25.89 | 3.86%
T4Q DY | Payout %
3.48% | 90.05%
T4Q NAPS | P/NAPS
0.11 | 6.27
T4Q NP Margin | ROE
14.28% | 24.23%
Market Buzz
News and Blogs
Company Profile
Sector: HEALTH CARE
Sector: HEALTH CARE
Subsector: HEALTH CARE PROVIDERS
Subsector: HEALTH CARE PROVIDERS
Description:
Optimax Holdings Sdn Bhd is a Malaysia-based company, which
provides eye specialist services. The Company offers a range of services in
medical ophthalmology at its specialist centers. The Company provides
treatments relating to eye and vision difficulties or impairment covering
refractive error, cataract, glaucoma, macular degeneration, diabetic
retinopathy and other eye diseases and disorders. The eye specialist services,
which are performed by eye surgeons include: refractive surgery comprising
laser vision correction and implant vision correction; treatment of eye
diseases and disorders including cataract surgery and other eye medical
treatment; consultation and dispensary services comprising doctor consultation
and medication; and oculoplastic surgery. The Company operates approximately 13
eye specialist centers across Malaysia.
Discussions
3 people like this. Showing 50 of 414 comments
27Oct2022, Bursa Securities has approved the Transfer FROM THE ACE MARKET TO THE MAIN MARKE
https://www.klsescreener.com/v2/announcements/view/3628057
2022-10-27 13:55
27Oct2022, Bursa Securities has approved the Transfer FROM THE ACE MARKET TO THE MAIN MARKE
https://www.klsescreener.com/v2/announcements/view/3628057
2022-10-27 13:55
Optimax is one of the most successful IPO on the healthcare ACE market. More successful for Cengild
2022-11-02 16:50
Really love the management team of Optimax. This company gives me the vibes like Harnlen. The growth potential of Optimax is endless. A lot of investors are putting money in healthcare; Eye-specialist services will keep expanding at an estimated CAGR of 6% as Malaysia aging population grows and increased demand for cataract treatments.
I am super bullish
2022-11-02 18:01
Trust me, take some money and put it into Optimax-WA and hold until 2026. You might be able to retire early
2022-11-02 18:05
Optimax bought
Optimax-wa also bought
Keep for long term and grannie will thanks me.
Drinking my starbuck first
2022-12-05 11:31
Optimax continue to fly fly fly..
strong company and investor is full of confident
2022-12-13 08:21
i see lots of potential in this optimax..invest and keep for promising profit return.
2023-01-13 09:41
stay tuned!!! more n more fantastic good news ahead!!! golden black horse which the price will be RM1.18 within few months!!!
2023-02-03 10:27
198. Regarding the issue of overcrowding in public health facilities, several measures will be undertaken.
The nation’s health capacity will be optimised by outsourcing patients from overcrowded hospitals to other hospitals, including university hospitals, military hospitals and private hospitals.
2023-02-27 00:27
Young ppl go for Lasik, seniors go for cataract--replacement of lens by artificial lens. Johor clinic will attract Singaporeans, when they come over for happy weekends! So, why down so much? I top up some already.
2023-02-28 16:27
Optimax Holdings - FY22: Earnings and DPS In-line
Date:
2023-03-01
Firm:
MAYBANK
Stock:
OPTIMAX
Price Target:
0.86
Price Call:
BUY
Last Price:
0.745
Upside/Downside:
+0.115 (15.44%)
Maintain BUY With Higher TP of MYR0.86
Optimax’s FY22 core net profit was within our expectations, coming in at MYR14.7m, making up 100%/97% of our/consensus FY22E earnings forecast. We adjust FY23E/FY24E by +2%/-11%, factoring for minor housekeeping and leaving room for potential delays in the construction of the Kempas hospital, which we now assume to commence operations by FY25 (prev. 2HFY24). We also introduce FY25E forecasts. Maintain BUY with a higher, DCF-based TP of MYR0.86 (prev. MYR0.84).
4Q22: Slight Margin Contraction as New Centres Open
4Q22 core net profit increased to MYR3.8m (+7% YoY, 4% QoQ) aided by maiden revenue contribution from newly opened eye specialist centres, bringing 4Q22 revenue to MYR28.4m (+6.8% YoY, -1.1% QoQ). We believe the new loss-making centres which opened in 2H22 were the cause of the EBITDA and PBT margin contractions, both YoY and QoQ. However, net profit margins remained level (+0.1 ppt YoY) or increased (+0.7ppts QoQ) as minority shareholder resident doctors shared in the losses of the new centres.
Steady FY22 Core Operations; DPS Expectations Met
We remain upbeat on Optimax’s core operations, with FY22 core net profit growing by 20% YoY to MYR14.7m, contributed by higher revenue of MYR108m (+22% YoY) which was driven by the re-opening of the economy, resilient demand for eye surgeries, and maiden revenue contribution from new centres. As expected, Optimax announced a second interim DPS of 1.2 sen, which will be paid out on 30 Mar 2023. This brings total DPS announced for FY22 to 2.4 sen (1.2 sen announced in 3Q22), which translates to total dividends of MYR13.0m and a dividend payout ratio of 88% of core net profit. We maintain our DPR assumptions of 80% for FY23E/FY24E/FY25E.
Expansion Plans Continue
In the 3Q22 results briefing, management shared that the Bahau ACC and Cheras satellite clinic were fully operational by end-3Q22, with 2 new satellite clinics slated to open in 4Q22. Management also shared intentions to open 7 new satellite clinics in FY23. Moving forward, we expect higher revenue contribution from consultations and treatment of other eye diseases, but minor margin contractions as new centres steadily mature.
Source: Maybank Research - 1 Mar 2023
2023-03-01 12:19
Summary
Optimax Holdings Bhd’s (OPTIMAX) 4Q22 core net profit improved 7.5% YoY to RM3.8m, bringing a 20.0% YoY increase on its FY22 core net profit to RM14.7m. The results came in within expectation, amounting to 102.1% of our full year forecast of RM14.4m. Meanwhile, an interim dividend of 1.2 sen per share, payable on 30th March 2023 was declared.
QoQ, core net profit showed an improvement of 4.1% to RM3.8m, despite a drop of 1.1% QoQ decline in its revenue to RM28.4m and this was mainly due to the lower minority interest of –RM0.2m registered for 4Q22 vs RM1.1m in 3Q22.
FY22 core net profit climbed 20.0% YoY, mainly attributed from (i) the increase in revenue arising from higher number of surgeries conducted amid economy reopening, (ii) effective marketing effort from ongoing promotions via online platforms, and (iii) better control over operating costs by leveraging on the experience gained from multiple lockdowns since March 2020.
Moving forward, OPTIMAX will continue to boost the capacity of its Ambulatory Care Centre (ACC) in regions other than central Malaysia by hiring more surgeons. Meanwhile, the group continued to seek strategic locations to set up more satellite clinics to support its growth, targeting 5 satellite clinics in FY23.
We expect its new ACC in Bahau, Negeri Sembilan and satellite clinic in Taman Sutera, Johor which were both established in FY22, would secure more patients and operate above break-even in the following 6-12 months, resulting in a higher margin for the group.
There is no material development pertaining to both MoU entered into with Selgate Healthcare Sdn. Bhd., as well as with Sena Resources Sdn. Bhd. and Kempas Eye Specialist Hospital Sdn. Bhd.
Valuation & Recommendation
Although the reported earnings came in within our expectations, we upgrade our FY23f earnings forecast by 6.9% to RM15.5m, taking into account the higher expectation on number of surgeries to be conducted amid economic reopening. Meanwhile, the core net profit forecast for FY24f is introduced at RM17.6m.
We maintained our BUY recommendation on OPTIMAX with a revised target price of RM1.15 (from RM1.07). The target price is based on the assigned target PER of 40.0x to our revised FY23f EPS of 2.9 sen.
Risks to our recommendation include the possible resurgence of Covid-19 infections which may result in postponement of surgeries. Besides, the inflationary pressure amid rising food and energy prices remains as threat to local economy.
Source: Mplus Research - 1 Mar 2023
2023-03-01 12:20
We maintained our BUY recommendation on OPTIMAX with a revised target price of RM1.15 (from RM1.07). The target price is based on the assigned target PER of 40.0x to our revised FY23f EPS of 2.9 sen.
2023-03-01 12:21
why buy an overvalued counter, when u can buy so many other undervalued gems?
2023-03-06 07:47
Guess Healthcare stock will be defensive choice when the market bad especially now.....hopefully Optimax is one of them :)
2023-03-16 16:18
I like and holding optimax.....only worry that ppl, especially the seniors, under the bad economy now, will opt for gov eye clinics as they are almost free!
2023-03-31 09:45
Something big is brewing...
More business means more profit this company took
2 months ago
Diversified into aesthetic business
https://www.thestar.com.my/business/business-news/2023/08/07/optimax-secures-license-to-offer-plastic-surgery-and-aesthetic-services
1 month ago
Post a Comment
Featured Posts
MQ Trader
MQ Trading Signals
Time
Signal
Duration
Type
2023-10-04 16:50:00
ADX
10 Mins
BUY
2023-10-04 16:50:00
TURTLE SYSTEM 20
10 Mins
BUY
2023-10-04 16:50:00
TURTLE SYSTEM 20
5 Mins
BUY
2023-10-04 16:50:00
TURTLE SYSTEM 55
5 Mins
BUY
2023-10-04 16:30:00
EMA 5
30 Mins
BUY
Apps
Top Articles
2
THE INVESTMENT APPROACH OF CALVIN TAN
BPLANT & KLK : A LOOK AT BOTH POSITIONS AT CURRENT CIRCUMSTANCE, Calvin Tan
3
4
save malaysia!
5
6
save malaysia!
8
#
Stock
Score
Daily Stocks
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Featured Advertisers / Partners
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
bojed
go go go!
2022-10-14 16:16